Personalized Medicine: Molecular Dx Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Personalized Medicine: Molecular Dx

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (34)	5/11/2010 11:12:48 AM
From: Steve Lokness	of 60

Response Genetics Signs Agreement with GlaxoSmithKline to Provide Proprietary BRAF Mutational Analysis Technology LOS ANGELES--(BUSINESS WIRE)-- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline (“GSK”). Under the terms of the agreement, GSK gains certain rights to Response Genetics’ proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones. Further financial details were not disclosed. The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase (B-raf), a protein involved in cell signaling and cellular growth and differentiation. Specific genetic mutations have been correlated with the development of certain forms of cancer. “As a provider of genetic testing services to GSK, we are pleased to continue to support GSK’s clinical trial program,” said Kathleen Danenberg, president and CEO of Response Genetics. “Through access to our proprietary technology, Response Genetics provides pharmaceutical companies with unique information and insights. By identifying specific genetic mutations, such as in the BRAF gene, we hope to enable the development of diagnosis tools for disease prognosis that may aid in treatment decisions.” Response Genetics’ holds other patented diagnostic technology and provides services to physicians through the company’s ResponseDX™ series of tests – proprietary PCR-based tests used to analyze the expression of genes that correlate with response to commonly used chemotherapy agents. ResponseDX: Colon™, ResponseDX: Lung™ and ResponseDX: Gastric™ genetic test panels are available in the United States through direct sales and through NeoGenomics Laboratories. In Australia and certain Asian countries, ResponseDX™ genetic tests are available through Genetic Technologies Ltd. All tests are performed through Response Genetics’ CLIA-certified laboratory.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next